merged_ftc-pharmacy-benefit-managers-drug-prices.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article states that "The F.T.C. has so far stopped short of bringing a lawsuit or other enforcement action against a benefit manager." They issued a critical report but haven't actually brought a lawsuit.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article doesn't mention the specific year when CVS Health acquired Caremark. It only notes that "By the end of 2018, each had become part of the same company as a giant insurer," but doesn't specify when the CVS-Caremark acquisition occurred.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>While the article mentions that benefit managers' practices with two generic cancer drugs "translated into nearly $1.6 billion in revenue over less than three years for the biggest three conglomerates," it doesn't specifically state how much patients overpaid for generic drugs.</other>